Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04457596
Title T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Tucatinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.